Abstract
The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 65-70 |
| Number of pages | 6 |
| Journal | Progress in Cardiovascular Diseases |
| Volume | 41 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 1998 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. / Jafri, S. M.; Borzak, S.; Goldberger, Jeffrey; Gheorghiade, M.
In: Progress in Cardiovascular Diseases, Vol. 41, No. 1, 01.01.1998, p. 65-70.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone
AU - Jafri, S. M.
AU - Borzak, S.
AU - Goldberger, Jeffrey
AU - Gheorghiade, M.
PY - 1998/1/1
Y1 - 1998/1/1
N2 - The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.
AB - The role antiarrhythmic agents in the post-MI patients has been investigated for several years. Recently, clinical trials have assessed the effects of amiodarone in the post-MI population. The Basel Antiarrhythmic Study of Infarct Survival (BASIS) trial showed a reduction in total mortality, sudden death, and life-threatening ventricular arrhythmias with amiodarone therapy. The European Myocardial Infarct Amiodarone Trial (EMIAT) did not show a mortality benefit, but amiodarone was associated with fewer antiarrhythmic deaths. The Canadian Amiodarone Myocardial Infarction Trial (CAMIAT) showed no significant impact on mortality, but arrhythmia deaths and resuscitated cardiac deaths were reduced. Amiodarone therapy after MI should be reserved for the treatment of symptomatic or sustained ventricular arrhythmias. The current data do not support routine use of amiodarone in all patients after MI.
UR - http://www.scopus.com/inward/record.url?scp=0031880762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031880762&partnerID=8YFLogxK
U2 - 10.1016/S0033-0620(98)80023-6
DO - 10.1016/S0033-0620(98)80023-6
M3 - Review article
C2 - 9717860
AN - SCOPUS:0031880762
VL - 41
SP - 65
EP - 70
JO - Progress in Cardiovascular Diseases
JF - Progress in Cardiovascular Diseases
SN - 0033-0620
IS - 1
ER -